This provider's $15.0M in total Medicare payments ranks in the 94th percentile of Clinical Laboratory providers nationally.
This provider's billing patterns fall within normal ranges for their specialty.
AI-generated analysis based on Medicare payment data.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2022 | $116.15 | $80.63 | 1.44x | $35.52 | $7.4M | 91.8K | 19 |
| 2023 | $210.51 | $145.47 | 1.45x | $65.04 | $7.6M | 52.4K | 20 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 81307 | Gene analysis (partner and localizer of brca2) full sequence analysis | 2.9K | $1.9M | $662.97 | 1.45x |
| 81321 | Gene analysis (phosphatase and tensin homolog), full sequence analysis | 2.9K | $1.7M | $588.00 | 2.04x |
| 81249 | Gene analysis (glucose-6-phosphate dehydrogenase) full sequence analysis | 2.7K | $1.6M | $588.00 | 1.02x |
| 81238 | Gene analysis (coagulation factor ix) full sequence analysis | 2.6K | $1.5M | $588.00 | 2.04x |
| 81223 | Gene analysis (cystic fibrosis transmembrane conductance regular) full gene sequence | 2.7K | $1.3M | $489.02 | 2.04x |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 99.7K | $1.2M | $11.76 | 1.17x |
| 81334 | Gene analysis (runt related transcription factor 1) targeted sequence analysis | 2.7K | $878.0K | $322.92 | 1.02x |
| 81311 | Gene analysis for cancer (neuroblastoma) | 2.7K | $788.2K | $289.87 | 1.02x |
| 81320 | Gene analysis (phospholipase c gamma 2) for common variants | 2.7K | $776.4K | $285.53 | 1.02x |
| 81279 | Gene analysis (janus kinase 2) targeted sequence analysis | 2.7K | $493.5K | $181.50 | 1.02x |
| 81339 | Gene analysis (mpl proto-oncogene, thrombopoietin receptor) sequence analysis of exon 10 | 2.7K | $493.5K | $181.50 | 1.02x |
| 81345 | Gene analysis (telomerase reverse transcriptase) targeted sequence analysis | 2.7K | $488.1K | $181.50 | 1.02x |
| 81305 | Gene analysis (myeloid differentiation primary response 88) for p.leu265pro variant | 2.7K | $467.4K | $171.89 | 1.02x |
| 81162 | Gene analysis (breast cancer 1 and 2) of full sequence and analysis for duplication or deletion variants | 180 | $321.9K | $1.8K | 1.34x |
| 81241 | Gene analysis (coagulation factor v) leiden variant | 2.7K | $192.3K | $71.90 | 2.04x |
| 81351 | Gene analysis (tumor protein 53) full sequence analysis | 278 | $174.9K | $629.01 | 1.43x |
| 81250 | Gene analysis (glucose-6-phosphatase, catalytic subunit) common variants | 2.7K | $152.4K | $57.32 | 2.04x |
| 81201 | Gene analysis (adenomatous polyposis coli), full gene sequence | 164 | $125.4K | $764.40 | 1.64x |
| 81209 | Gene analysis (bloom syndrome, recq helicase-like) | 2.6K | $101.9K | $38.52 | 1.02x |
| 81242 | Gene analysis (fanconi anemia, complementation group c) common variant | 2.6K | $94.8K | $35.89 | 2.04x |
This provider submits charges 1.44 times higher than what Medicare actually pays.
A markup ratio of 1.44x means for every $100 Medicare pays, this provider initially charges $144. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in FL for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Quest Diagnostics Clinical Laboratories Inc | Tampa, FL | $1.0B | ⚠️ Flagged |
| Laboratory Corporation Of America | Tampa, FL | $463.1M | ⚠️ Flagged |
| Quest Diagnostics Clinical Laboratories Inc | Miramar, FL | $417.1M | ⚠️ Flagged |
| American Health S, Llc | Davie, FL | $175.7M | ✓ Clear |
| Ameripath Florida Llc | Pompano Beach, FL | $80.1M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data